Comparative Pharmacology
Head-to-head clinical analysis: BETOPTIC S versus LABETALOL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETOPTIC S versus LABETALOL HYDROCHLORIDE.
BETOPTIC S vs LABETALOL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Betaxolol is a cardioselective beta-1 adrenergic receptor antagonist. In ophthalmic use, it reduces intraocular pressure by decreasing the production of aqueous humor, likely through blockade of beta-2 receptors in the ciliary epithelium.
Labetalol is a non-selective beta-adrenoceptor blocker and selective alpha-1 adrenoceptor blocker. It reduces myocardial contractility, heart rate, and peripheral vascular resistance.
Instill 1 drop in the affected eye(s) twice daily.
Oral: Initial 100 mg twice daily, titrate up to 200-400 mg twice daily; maximum 2400 mg/day. IV: 20 mg slow IV over 2 minutes, then 40-80 mg every 10 minutes as needed up to 300 mg total; or continuous IV infusion at 0.5-2 mg/min.
None Documented
None Documented
Terminal elimination half-life is approximately 4–6 hours in adults; prolonged in renal impairment and in elderly patients due to decreased clearance.
Terminal elimination half-life: 6-8 hours. In renal impairment, half-life may be slightly prolonged but not clinically significant; in hepatic impairment, half-life may be significantly prolonged.
Renal: 0.3% unchanged; extensive hepatic metabolism to inactive metabolites; biliary/fecal elimination of metabolites accounts for the majority of excretion; total renal elimination of drug and metabolites is approximately 80%, with the remainder via feces.
Primarily hepatic metabolism; ~5% excreted unchanged in urine; ~55-60% as glucuronide conjugates in urine; fecal excretion <5%.
Category C
Category A/B
Beta-Blocker
Alpha/Beta-Blocker